...
首页> 外文期刊>Transplant immunology >Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression.
【24h】

Indefinite mouse heart allograft survival in recipient treated with CD4(+)CD25(+) regulatory T cells with indirect allospecificity and short term immunosuppression.

机译:用间接同种特异性和短期免疫抑制作用用CD4(+)CD25(+)调节性T细胞治疗的受体中的小鼠心脏异体移植存活期不确定。

获取原文
获取原文并翻译 | 示例

摘要

CD4(+)CD25(+) regulatory T cells (Tregs) play a crucial role in controlling immune responses. It is an appealing strategy to harness Tregs for adoptive cell therapy to induce tolerance to allografts. Several approaches have been developed to expand antigen-specific Tregs. Despite the large body of experimental data from murine studies demonstrating the great potential of these cells for clinical application, Treg adoptive transfer therapy was used in immunodeficient animals or in strain combinations with limited histiocompatibility. The aim of this study was to investigate whether Treg lines can protect from allograft rejection in a fully MHC-mismatched strain combination and whether the presence of Tregs with indirect allospecificity offered an advantage compared to self-reactive Tregs. Treg lines with self-specificity or with indirect allospecificity were generated by stimulating BL/6 CD4(+)CD25(+) T cells with autologous immature DCs either unpulsed or pulsed with K(d) peptide. The Treg lines were injected into recipient mice in combination with temporary depletion of CD8(+) T cells and a short course of Rapamycin. The data demonstrate that Treg lines with indirect allospecificity can be generated and most importantly they can induce indefinite survival of BALB/c hearts transplanted into BL/6 recipients when combined with short term immunosuppression. However, the Treg lines with self-specificity were only slightly less effective. The data presented in this study demonstrate the potential of ex vivo expanded Treg lines for adoptive cell therapy to promote transplantation tolerance.
机译:CD4(+)CD25(+)调节性T细胞(Tregs)在控制免疫反应中起关键作用。利用Treg进行过继细胞治疗以诱导对同种异体移植的耐受性是一种有吸引力的策略。已经开发了几种方法来扩展抗原特异性Treg。尽管来自鼠类研究的大量实验数据证明了这些细胞在临床上的巨大潜力,但Treg过继转移疗法已用于免疫缺陷动物或组织相容性有限的菌株组合中。这项研究的目的是调查在完全MHC不匹配的菌株组合中Treg品系是否可以防止同种异体移植排斥,以及与自身反应性Treg相比,具有间接同种特异性的Tregs是否具有优势。具有自特异性或间接同种特异性的Treg系是通过用未脉冲或用K(d)肽脉冲的自体未成熟DC刺激BL / 6 CD4(+)CD25(+)T细胞而产生的。将Treg品系与CD8(+)T细胞的暂时耗竭和雷帕霉素的短疗程相结合,注入受体小鼠体内。数据表明,可以产生具有间接同种异体特异性的Treg品系,最重要的是,与短期免疫抑制相结合,它们可以诱导移植到BL / 6受体中的BALB / c心脏的无限期存活。但是,具有自我特异性的Treg品系的效果稍差。这项研究中提供的数据证明了离体扩增的Treg品系在过继细胞治疗中提高移植耐受性的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号